COST-EFFECTIVENESS OF TOFACTINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS AFTER CONVENTIONAL THERAPY IN SPAIN

被引：0
|
作者：
Taxonera, C. [1 ]
de Andres-Nogales, F. [2 ]
Garcia, S. [3 ]
Sanchez-Guerrero, A. [4 ]
Menchen, B. [4 ]
Peral, C. [5 ]
Cabez, A. [5 ]
Gomez, S. [5 ]
Lopez, A. [6 ]
Casado, M. A. [2 ]
Menchen, L. [7 ]
机构：
[1] Hosp Clin San Carlos, Madrid, Spain
[2] PORIB, Pozuelo De Alarcon M, Spain
[3] Hosp Univ Miguel Servet, Zaragoza, Spain
[4] Hosp Univ Puerta de Hierro Majadahonda, Madrid, Spain
[5] Pfizer SLU, Madrid, Spain
[6] Pfizer SLU, Madrid M, Spain
[7] Hosp Gen Univ Gregorio Maranon, Madrid, Spain
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PGI17
引用
收藏
页码：S619 / S619
页数：1
相关论文
共 50 条
  • [31] Etrolizumab in moderate-to-severe ulcerative colitis
    Armuzzi, Alessandro
    Felice, Carla
    LANCET, 2014, 384 (9940): : 285 - 286
  • [32] Cost Effectiveness of Tofacitinib for the Treatment of Moderate to Severe Active Ulcerative Colitis in Colombia
    Fabio Gil
    Fabian Juliao-Baños
    Luisa Amador
    Natalia Castano
    Juan Manuel Reyes
    PharmacoEconomics - Open, 2022, 6 : 837 - 846
  • [33] Cost Effectiveness of Tofacitinib for the Treatment of Moderate to Severe Active Ulcerative Colitis in Colombia
    Gil, Fabio
    Juliao-Banos, Fabian
    Amador, Luisa
    Castano, Natalia
    Reyes, Juan Manuel
    PHARMACOECONOMICS-OPEN, 2022, 6 (06) : 837 - 846
  • [34] Medical therapy versus surgery in moderate-to-severe ulcerative colitis
    Fiorino, Gionata
    Danese, Silvio
    Giacobazzi, Giovanni
    Spinelli, Antonino
    DIGESTIVE AND LIVER DISEASE, 2021, 53 (04) : 403 - 408
  • [35] Are We Ready for Combination Therapy in Moderate-to-Severe Ulcerative Colitis?
    Lee, Yeong Yeh
    Gangireddy, Venugopalareddy
    Khurana, Sandeep
    Rao, Satish S. C.
    GASTROENTEROLOGY, 2014, 147 (02) : 544 - 544
  • [36] COST-EFFECTIVENESS OF APREMILAST IN MODERATE-TO-SEVERE PSORIASIS IN CANADA
    Cawston, H.
    Damera, V
    Ektare, V
    Shear, N. H.
    Tencer, T.
    Liu, F. F.
    VALUE IN HEALTH, 2016, 19 (07) : A587 - A587
  • [37] Cost-effectiveness of abatacept for moderate-to-severe rheumatoid arthritis
    Tsao, Nicole W.
    Shojania, Kam
    Marra, Carlo A.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (01) : 9 - 18
  • [38] COST-EFFECTIVENESS OF CARDIAC RESYNCHRONISATION THERAPY FOR PATIENTS WITH MODERATE-TO-SEVERE HEART FAILURE
    Neyt, M.
    Stroobandt, S.
    Obyn, C.
    Camberlin, C.
    Devriese, S.
    De Laet, C.
    Van Brabandt, H.
    VALUE IN HEALTH, 2011, 14 (07) : A253 - A253
  • [39] Cost-Effectiveness Analysis of Vedolizumab Compared With Infliximab in Anti-TNF-α-Naive Patients With Moderate-to-Severe Ulcerative Colitis in China
    Zhou, Ting
    Sheng, Yanan
    Guan, Haijing
    Meng, Rui
    Wang, Zijing
    FRONTIERS IN PUBLIC HEALTH, 2021, 9
  • [40] Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan
    Taku Kobayashi
    Masato Hoshi
    Akira Yuasa
    Shoko Arai
    Mitsunobu Ikeda
    Hiroyuki Matsuda
    Seok-Won Kim
    Toshifumi Hibi
    PharmacoEconomics, 2023, 41 : 589 - 604
12345